September 10, 2011 - The State Council Information Office held a series of press conferences on the theme of “promoting high-quality development” on the morning of the 10th, Yan Qinghui, deputy director of the State Medical Insurance Bureau, said at the meeting that the medical insurance sector will vigorously promote the expansion of the quality of the collection of medicine and mining. Continuously expand the coverage of collection, carry out a new batch of national organization drugs and high-value medical supplies collection, will be cochlear implants and other high-value medical supplies into the collection.

Yan Qinghui introduced, the effectiveness of the collection work can be recognized from three aspects:

First, the burden of drug use by the public has been reduced, and the accessibility and quality of drugs have been improved. For example, hepatitis B antiviral drugs entecavir and tenofovir, etc., the annual cost of patients before the collection and procurement is as high as about 4,000-5,000 yuan, and after the collection and procurement, the annual cost is reduced to about 100-200 yuan. Clinical studies by healthcare organizations have shown that the treatment and standardization rates of antiviral for hepatitis B patients have increased dramatically. Another example is that the price of insulin has been significantly reduced after the collection and procurement, and the proportion of the use of third-generation insulin with better clinical performance has increased from 58% before the collection and procurement to more than 70%.

Secondly, it promotes the healthy and high-quality development of the pharmaceutical industry. Collective purchasing has reshaped the ecology of China's pharmaceutical industry and changed the development thinking of the pharmaceutical industry. In the collection before, pharmaceutical enterprises heavy marketing channel competition, light quality and research and development; collection provides a fair competition, sunshine competition platform, so that good products through the collection can quickly open the market, from the public inquiry thoracic aortic stent and other drugs and consumables price governance situation, some pharmaceutical products to reduce the price of the space is mainly from the compression of the circulation area costs, the production of research and development of enterprises, the actual earnings impact is relatively The impact on the actual revenue of production and R&D enterprises is relatively small. At the same time, the freed-up cost space can be used for innovation, so that more enterprises will shift their focus to quality improvement, scale production and innovation.

Third, it is to promote the return of public hospitals and medical institutions to the public welfare. Collective purchasing cuts off the gray chain of interests in the circulation of drugs and consumables, and makes the prescribing behavior of medical personnel more standardized. For example, the intensity of antibiotic use in the “worst drug abuse area” has continued to decline from 37.8 in 2018 to 33.8 in 2022.The collection and procurement supporting policy also focuses on increasing the sunshine income of medical institutions and medical personnel. According to the policy, the medical insurance funds saved through collective procurement will be retained in a certain percentage of the balance for medical institutions after assessment, and a considerable part of it will be used for the salary reform of medical personnel; some regions have also carried out a pilot of charging for pharmacy services, reflecting the value of the technical labor of physicians and pharmacists, which creates the conditions for the high-quality development of medical institutions and the return to the public welfare.

Yan Qinghui pointed out that the next step, the medical insurance department will vigorously promote the expansion of the quality of the pharmaceutical collection and procurement. Continuously expand the coverage of collection and mining, carry out a new batch of state-organized drugs and high-value medical supplies collection and mining, will be cochlear implants and other high-value medical supplies into the collection and mining scope. It will strengthen regional coordination, focusing on guiding localities to promote the collective procurement of medicines and consumables such as proprietary Chinese medicines, Chinese medicine tablets and in-vitro diagnostic reagents. It will smoothly promote successive purchases, strengthen the refined management of the implementation of collective purchasing, and work with relevant departments to strengthen the management measures for the use, supply and monitoring of the selected products, so as to urge the selected products to be admitted to hospitals in a timely manner and given priority for use, and also take measures to solidify the responsibility of the selected enterprises for ensuring quality and supply.